The Korean journal of internal medicine

  • 제32권5호
  • /
  • Pages.798-804
  • /
  • 2017
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Targeted therapy of ovarian cancer including immune check point inhibitor

  • Kim, Jin Young (Division of Hematology/Oncology, Department of Internal Medicine, Keimyung University Dongsan Medical Center) ;
  • Cho, Chi Heum (Department of Obstetrics and Gynecology, Keimyung University Dongsan Medical Center) ;
  • Song, Hong Suk (Division of Hematology/Oncology, Department of Internal Medicine, Keimyung University Dongsan Medical Center)
  • 투고 : 2016.12.28
  • 심사 : 2017.01.03
  • 발행 : 2017.09.01
⟨ 이전 논문 다음 논문 ⟩

초록

Epithelial ovarian cancer is the eighth most common cause of cancer-related deaths in women because most patients present with advanced stage disease at the time of diagnosis. Although cytoreductive surgery and platinum-based chemotherapy remain the gold standards of treatment, the recurrence rate of ovarian cancer remains high. Attempts to improve this standard two-drug chemotherapy by adding a third cytotoxic drug have failed to affect either progression-free survival or overall survival and have resulted in an increase in toxic side effects. Some anti-angiogenic agents, poly(ADP-ribose) polymerase, and immune checkpoint inhibitors have shown efficacy in early stages of development for the treatment of epithelial ovarian cancer. As demonstrated in recent clinical trials, the use of bevacizumab, cediranib, pazopanib, olaparib, and rucaparib, either alone or in combination with conventional cytotoxic agents, improves progression-free survival. Trials on immune checkpoint inhibitors such as nivolumab have revealed prolonged responses in a small set of ovarian cancer cases but require further exploration. In this review, we discuss the role of targeted therapies against ovarian cancer, including the use of immune checkpoint inhibitors.

키워드

참고문헌

  1. National Cancer Information Center. Percentage of deaths from 10 cancer deaths among men in 2015 [Internet]. Goyang (KR): National Cancer Information Center, c2012 [cited 2017 Aug 3]. Available from: http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040202000000.
  2. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary: FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S161-S192. https://doi.org/10.1016/S0020-7292(06)60033-7
  3. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009;19 Suppl 2:S63-S67. https://doi.org/10.1111/IGC.0b013e3181c104fa
  4. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced- stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:1419-1425. https://doi.org/10.1200/JCO.2008.19.1684
  5. du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006;24:1127-1135. https://doi.org/10.1200/JCO.2005.03.2938
  6. Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006;98:1036-1045. https://doi.org/10.1093/jnci/djj296
  7. Hoskins P, Vergote I, Cervantes A, et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 2010;102:1547-1556. https://doi.org/10.1093/jnci/djq362
  8. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. https://doi.org/10.1056/NEJMoa052985
  9. Meehan RS, Chen AP. New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract 2016;3:3. https://doi.org/10.1186/s40661-016-0024-7
  10. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v23-v30. https://doi.org/10.1093/annonc/mdq244
  11. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-1338. https://doi.org/10.1016/S0140-6736(09)61157-0
  12. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013;14:1020-1026. https://doi.org/10.1016/S1470-2045(13)70363-2
  13. Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014;15:396-405. https://doi.org/10.1016/S1470-2045(14)70049-X
  14. Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 2016;374:738-748. https://doi.org/10.1056/NEJMoa1505067
  15. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376:1155-1163. https://doi.org/10.1016/S0140-6736(10)61268-8
  16. National Comprehensive Cancer Network. Ovarian cancer [Internet]. Fort Washington (PA): National Comprehensive Cancer Network, c2017 [cited 2017 Aug 3]. Available from: https://www.nccn.org.
  17. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26-35. https://doi.org/10.1634/theoncologist.5-1-26
  18. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-393. https://doi.org/10.1200/JCO.1991.9.3.389
  19. Lokadasan R, James FV, Narayanan G, Prabhakaran PK. Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments. Ecancermedicalscience 2016;10:626.
  20. Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996;74:1105-1115.
  21. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-2483. https://doi.org/10.1056/NEJMoa1104390
  22. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-2496. https://doi.org/10.1056/NEJMoa1103799
  23. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015;16:928-936. https://doi.org/10.1016/S1470-2045(15)00086-8
  24. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-2045. https://doi.org/10.1200/JCO.2012.42.0505
  25. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32:1302-1308. https://doi.org/10.1200/JCO.2013.51.4489
  26. Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 2014;32:1309-1316. https://doi.org/10.1200/JCO.2013.51.4240
  27. Aghajanian C, Nycum L, Goff B, et al. Updated overall survival analysis in OCEANS, a randomized phase III trial of gemcitabine (G) + carboplatin (C) and bevacizumab (BV) or placebo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Proceedings of the 37th Congress of the European Society for Medical Oncology (ESMO); 2012 Sep 28-Oct 2; Vienna (AT). Austria: Oxford University Press, 2012: 319.
  28. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(18 Suppl):327s.
  29. Witteveen P, Lortholary A, Fehm T, et al. Final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC). Eur J Cancer 2013;49 Suppl 3:S3.
  30. Friedlander M, Hancock KC, Rischin D, et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119:32-37. https://doi.org/10.1016/j.ygyno.2010.05.033
  31. du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014;32:3374-3382. https://doi.org/10.1200/JCO.2014.55.7348
  32. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27:5601-5606. https://doi.org/10.1200/JCO.2009.23.2777
  33. Raja FA, Griffin CL, Qian W, et al. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer 2011;105:884-889. https://doi.org/10.1038/bjc.2011.334
  34. Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013;19:1381-1388. https://doi.org/10.1038/nm.3369
  35. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-1392. https://doi.org/10.1056/NEJMoa1105535
  36. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol 2014;15:852-861. https://doi.org/10.1016/S1470-2045(14)70228-1
  37. McNeish IA, Oza AM, Coleman RL, et al. Results of ARIEL2: a phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J Clin Oncol 2015;33(15 Suppl):5508.
  38. Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomized phase 2 study. Lancet Oncol 2014;15:1207-1214. https://doi.org/10.1016/S1470-2045(14)70391-2
  39. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712-4717. https://doi.org/10.1073/pnas.0830997100
  40. Hamanishi J, Mandai M, Ikeda T, et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO- 4538) in patients with platinum-resistant ovarian cancer. J Clin Oncol 2014;32(15 Suppl):5511.

피인용 문헌

  1. ZNF277 regulates ovarian cancer cell proliferation and invasion through inhibition of PTEN vol.12, pp.None, 2017, https://doi.org/10.2147/ott.s192553
  2. Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways vol.10, pp.10, 2019, https://doi.org/10.1038/s41419-019-2013-3
  3. Epithelial-mesenchymal interconversions in ovarian cancer: The levels and functions of E-cadherin in intraabdominal dissemination vol.14, pp.1, 2020, https://doi.org/10.4081/oncol.2020.475
  4. Chitosan is a potential inhibitor of ovarian cancer: Molecular aspects vol.72, pp.4, 2017, https://doi.org/10.1002/iub.2206
  5. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer vol.12, pp.12, 2020, https://doi.org/10.18632/aging.103199
  6. Sensitive competitive label-free electrochemical immunosensor for primal detection of ovarian cancer vol.74, pp.8, 2017, https://doi.org/10.1007/s11696-020-01100-w
  7. Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer vol.10, pp.None, 2017, https://doi.org/10.1038/s41598-020-63634-z
  8. Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer vol.25, pp.4, 2017, https://doi.org/10.1080/14728214.2020.1836155
  9. Pharmacological Inhibition of BAD Ser99 Phosphorylation Enhances the Efficacy of Cisplatin in Ovarian Cancer by Inhibition of Cancer Stem Cell-like Behavior vol.3, pp.6, 2017, https://doi.org/10.1021/acsptsci.0c00064
  10. SRT2183 impairs ovarian cancer by facilitating autophagy vol.12, pp.23, 2020, https://doi.org/10.18632/aging.104126
  11. G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients vol.12, pp.None, 2021, https://doi.org/10.3389/fendo.2021.564002
  12. LncRNA ARAP1-AS1 aggravates the malignant phenotypes of ovarian cancer cells through sponging miR-4735-3p to enhance PLAGL2 expression vol.73, pp.3, 2017, https://doi.org/10.1007/s10616-021-00463-6
  13. miR-362-3p acts as a tumor suppressor by targeting SERBP1 in ovarian cancer vol.14, pp.1, 2017, https://doi.org/10.1186/s13048-020-00760-2